Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking with the NHS and other Healthcare OrganisationsDonations and GrantsDonations of Goods, Services and Benefit in KindOncology Donation: Multiple Myeloma Real-World Evidence PlatformOncology Donation: Multiple Myeloma Real-World Evidence PlatformSupporting NHS healthcare professionals with auditing and real-world evidence generation to improve outcomes in multiple myeloma patients.

Pfizer UK will provide subscription access to the Ledidi real-world evidence platform. Ledidi is a GDPR-compliant cloud-based all-in-one platform for collecting, structuring, analysing and visualising data with a built-in mechanism of collaboration between clinicians and institutions. The platform allows for the creation of registries, research projects and multi-centre collaborations with real time statistical analytics. The platform also facilitates the upload of existing data sets into the platform, with functionality which includes the automatic sorting and categorising of these data. The sharing of data between collaborators is controlled by the lead trust and the platform does not limit the number of projects/registries/collaborations.
 

The Pfizer donation will consist of:


Hospital trusts utilising the Ledidi platform will retain ownership and control of any data that is uploaded: neither Pfizer nor Ledidi will be able to access or be privy to any data on the site. All patient level data held on the platform with be anonymised. Any sharing of data by the trust is through their own collaborations either within or outside of the platform and Ledidi is required to maintain adherence to data privacy laws.

Any hospitals within the UK NHS that treats multiple myeloma can to apply for this service donation. Forty subscriptions in total are available and NHS trusts will be selected to receive this donation on a first-come, first-served basis and based on the below criteria:


All applications will be reviewed in order of application date and time on a first-come, first-served basis. Once all subscriptions have been allocated then the application portal will close. If a large number of applications are received all at once then the application portal may close until the backlog of applications is reviewed or until all grants are allocated, whichever occurs first.

All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Prime/Core.  Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.

If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided. Disclosure of this Pfizer donation will be required by each recipient hospital.

For further information on the data privacy and security of the Ledidi Real-World Evidence platform please refer to the following links.

Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.  Pfizer accepts no responsibility for the content or services of the linked site.

All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.

If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided at a later date. Disclosure of this Pfizer donation will be required by each recipient hospital.

Apply for the Multiple Myeloma Real-World Evidence Platform
PP-UNP-GBR-9193 / June 2024
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.